Evidence map›Paper›PMID 39197422›Full record

GuidelineDigestion2024

Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023.

Eikichi Ihara, Noriaki Manabe, Hidenori Ohkubo, Naotaka Ogasawara, Haruei Ogino, Kazuki Kakimoto, Motoyori Kanazawa, Hidejiro Kawahara, Chika Kusano, Shiko Kuribayashi and 27 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Digestion, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Eikichi IharaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Noriaki ManabeGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Hidenori OhkuboGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Naotaka OgasawaraGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Haruei OginoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Kazuki KakimotoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Motoyori KanazawaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Hidejiro KawaharaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Chika KusanoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Shiko KuribayashiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Akinari SawadaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Tomohisa TakagiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Shota TakanoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Toshihiko TomitaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Toshihiro NoakeGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Mariko HojoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Ryota HokariGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Tatsuhiro MasaokaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Tomohiko MachidaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Noboru MisawaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Yoshiyuki MishimaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Hiroshi YajimaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Sayuri YamamotoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Hiroshi YamawakiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Tatsuya AbeGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Yasumi ArakiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Kunio KasugaiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Takeshi KamiyaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Akira ToriiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Atsushi NakajimaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Koji NakadaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Shin FukudoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Yasuhiro FujiwaraGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Hiroto MiwaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Hiromi KataokaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Akihito NagaharaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Kazuhide HiguchiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Japan Gastroenterological Association (JGA) published the first version of clinical guidelines for chronic diarrhea 2023. These guidelines describe the definition, classification, diagnostic criteria, diagnostic testing methods, epidemiology, pathophysiology, and treatment of chronic diarrhea, and provide flowcharts for the diagnosis and treatment of chronic diarrhea based on the latest evidence. Treatment for chronic diarrhea begins by distinguishing secondary chronic constipation with a clear etiology, such as drug-induced diarrhea, food-induced diarrhea, systemic disease-associated diarrhea, infection-associated diarrhea, organic disease-associated diarrhea, and bile acid diarrhea. The first line of treatment for chronic diarrhea in the narrow sense, defined in these guidelines as functional diarrhea in routine medical care, is lifestyle modification and dietary therapy. The first medicines to be considered for oral treatment are probiotics for regulating the gut microbiome and anti-diarrheals. Other medications, such as 5HT3 receptor antagonists, anticholinergics, Kampo medicine, psychotherapy, antibiotics, bulking agents, adrenergic agonists, and somatostatin analogs, lack sufficient evidence for their use, highlighting a challenge for future research. This Clinical Guidelines for Chronic Diarrhea 2023, which provides the best clinical strategies for treating chronic diarrhea in Japan, will also be useful for medical treatment worldwide.

Indexed as

DiarrheaEvidence-Based MedicineProbioticsAntidiarrhealsChronic DiseaseHumansJapanAntidiarrhealsChronic diarrheaDiarrhea-predominant irritable bowel syndromeFunctional diarrheaGuidelines

Identifiers

PMID39197422
PMCPMC11633876

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.